Richard S. Bedlack, MD, PhD, MS, leads a team of 75 international experts in investigating alternative and off-label treatments that target people with amyotrophic lateral sclerosis (ALS). Dr Bedlack founded an organization, ALS Untangled, which has conducted a number of in-depth investigations and systematic reviews of such treatments.
Earning his MD and PhD at the University of Connecticut, and his MS in the Duke Clinical Research Training Program, Dr Bedlack presently engages in epidemiological, basic and clinical research on ALS. He is associate professor of neurology at Duke University and director of that University’s ALS clinic, one of the largest and most comprehensive of its kind in the world. For four years in a row, he has won the distinction of one of America's Best Doctors, an award given to the top 5% physicians in the country. In 2009 he was selected National Patient Advocate of the Year by the American Academy of Neurology.
“Scrutinizing enrollment in ALS clinical trials: room for improvement?” (with DM Pastula, E Welsh, D Pulley & ME Cudkowicz), Amyotrophic Lateral Sclerosis, 2008 Oct; 9(5):257-265. [DOI]
